


Julia Bruno-Colmenárez,^a
Alfredo Usubillaga,^b Nancy
Khouri^b and Graciela Díaz de
Delgado^{a*}^aLaboratorio de Cristalografía, LNDRX, Facultad de Ciencias, Universidad de Los Andes, Mérida 5101, Venezuela, and ^bGrupo de Productos Naturales y Química Medicinal, Facultad de Farmacia, Universidad de Los Andes, Mérida 5101, Venezuela

Correspondence e-mail: diaz@ula.ve

Key indicators

Single-crystal X-ray study
T = 291 K
Mean $\sigma(\text{C}-\text{C}) = 0.006 \text{ \AA}$
R factor = 0.053
wR factor = 0.121
Data-to-parameter ratio = 9.4For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.Cubebin, a lignan isolated from *Aristolochia odoratissima* L.The structure of cubebin [systematic name: 3,4-bis(1,3-benzodioxol-5-ylmethyl)tetrahydrofuran-2-ol], $\text{C}_{20}\text{H}_{20}\text{O}_6$, is stabilized by $\text{O}-\text{H}\cdots\text{O}$ and $\text{C}-\text{H}\cdots\text{O}$ hydrogen bonds.Received 20 March 2007
Accepted 21 March 2007

Comment

Cubebin is a dibenzylbutyrolactone lignan, commonly found in coniferae and in the wood, roots and resin of many plants. It has been isolated from hinokiol (Ishiguro, 1936) and obtained by synthesis (Battersbee *et al.* 1969). Cubebin and its derivatives show a range of biological activities; recent studies report their analgesic, anti-inflammatory and trypanocidal activity (Bastos *et al.*, 2001; Souza *et al.*, 2004; de Souza *et al.*, 2005; da Silva *et al.*, 2005). Our material was isolated from *Aristolochia odoratissima* L. (Usubillaga *et al.*, 2005), which grows in the humid lowlands of the Maracaibo Lake (Venezuela). This plant contains aristolochic acid and is used as an anti-ophidian remedy.Fig. 1 shows the molecular structure of the title compound, (I), with the atom- and ring-labelling scheme. The five-membered ring C adopts an envelope conformation, with C2 as the flap atom. The substituents at C2 and C3 on ring C are *trans* to each other.A search of the Cambridge Structural Database (Version 5.28; Allen, 2002) resulted in only one similar structure, a lignan with the same molecular formula isolated from *Daphne tangutica* Maxim, called (–)-dihydrosesamin, (II) (Lin-Gen *et al.*, 1983).

Experimental

Cubebin was extracted from the ground roots of *Aristolochia odoratissima* L. by treatment with *n*-pentane. Upon concentration of the pentane extract to half its volume, a precipitate was obtained which was filtered and crystallized from CHCl_3 –hexane (1:1). Recrystallization from pentane yielded colourless needles (140 mg; m.p. 403–406 K). Mass spectrum: M^+ 356 ($\text{C}_{20}\text{H}_{20}\text{O}_6$, 32%), 338 ($M^+ - \text{H}_2\text{O}$, 12%), 203 (15%), 135 (100%). ¹H NMR (400 MHz, CDCl_3 , δ , p.p.m.): 6.68 (*d*, 2H, H11 and H19), 6.62 (*m*, 2H, H12 and H20), 6.47 (*s*, 2H, H7 and H15), 5.88 (*s*, 4H, $\text{OCH}_2\text{O} \times 2$), 5.12 (*d*, 1H, H1), 3.90 (*t*, 1H, H4A), 3.72 (*t*, 1H, H4B), 2.64 (*m*, 4H, H13A,B and H5A,B), 2.09 (*m*, 1H, H3) 2.06 (*m*, 1H, H2).

Crystal data

$C_{20}H_{20}O_6$
 $M_r = 356.36$
 Monoclinic, $P2_1$
 $a = 11.631(2) \text{ \AA}$
 $b = 5.5969(10) \text{ \AA}$
 $c = 13.577(2) \text{ \AA}$
 $\beta = 99.548(3)^\circ$

$V = 871.6(3) \text{ \AA}^3$
 $Z = 2$
 Mo $K\alpha$ radiation
 $\mu = 0.10 \text{ mm}^{-1}$
 $T = 291 \text{ K}$
 $0.3 \times 0.2 \times 0.1 \text{ mm}$

Data collection

Bruker SMART CCD area-detector diffractometer
 Absorption correction: multi-scan (SADABS; Sheldrick, 1996)
 $T_{\min} = 0.944$, $T_{\max} = 0.989$

5459 measured reflections
 2212 independent reflections
 962 reflections with $I > 2\sigma(I)$
 $R_{\text{int}} = 0.070$

Refinement

$R[F^2 > 2\sigma(F^2)] = 0.053$
 $wR(F^2) = 0.121$
 $S = 0.99$
 2212 reflections
 235 parameters

1 restraints
 H-atom parameters constrained
 $\Delta\rho_{\text{max}} = 0.15 \text{ e \AA}^{-3}$
 $\Delta\rho_{\text{min}} = -0.16 \text{ e \AA}^{-3}$

Table 1

Hydrogen-bond geometry (\AA , $^\circ$).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$O2-H2A\cdots O1^i$	0.82	1.95	2.744 (4)	164
$C9-H9A\cdots O4^{ii}$	0.97	2.59	3.182 (6)	120
$C13-H13A\cdots O2$	0.97	2.51	2.838 (5)	100

Symmetry codes: (i) $-x + 1, y + \frac{1}{2}, -z + 2$; (ii) $-x + 2, y + \frac{1}{2}, -z + 1$.

H atoms were placed in calculated positions and refined using a riding model, with $C-H = 0.93-0.98 \text{ \AA}$ and $O-H = 0.82 \text{ \AA}$, and with $U_{\text{iso}}(H) = 1.2U_{\text{eq}}(C,O)$. In the absence of appreciable anomalous scattering, Friedel equivalents were merged before the final refinement cycles. The configuration reported in the literature was used for the refinement.

Data collection: SMART (Bruker, 1998); cell refinement: SMART; data reduction: SAINT (Bruker, 1998); program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: DIAMOND (Brandenburg, 2001); software used to prepare material for publication: PLATON (Spek, 2003), enCIFer (Allen *et al.*, 2004) and publCIF (Westrip, 2007).

The authors acknowledge FONACIT grant No. LAB-97000821 and CDCHT grant No. FA103 for financial support. Part of this work made use of the Materials Research Laboratory-UCSB Central Facilities, supported by the MRSEC Programme of the National Science Foundation under Award No. DMR00-80034.

References

Allen, F. H. (2002). *Acta Cryst.* **B58**, 380–388.
 Allen, F. H., Johnson, O., Shields, G. P., Smith, B. R. & Towler, M. (2004). *J. Appl. Cryst.* **37**, 335–338.
 Bastos, J. K., Carvalho, J. C. T., de Souza, G. H. B., Pedrazzi, A. H. P. & Sarti, S. J. (2001). *J. Ethnopharmacol.* **75**, 279–282.




Figure 1

The molecular structure of the title compound, with the atom- and ring labelling scheme. Displacement ellipsoids are drawn at the 50% probability level.




Figure 2

View along the b axis of the packing arrangement and intermolecular hydrogen bonds for the title compound. Blue dashed lines indicate $O2-H2A\cdots O1$ hydrogen bonds and green dashed lines $C9-H9A\cdots O4$.

- Battersbee, J. E., Burden, R. S., Crombie, L. & Whiting, D. A. (1969). *J. Chem. Soc. C*, pp. 2470–2477.
 Brandenburg, K. (2001). *DIAMOND*. Release 2.1e. Crystal Impact GbR, Bonn, Germany.
 Bruker (1998). SMART (Version 5.050) and SAINT (Version 5.01). Bruker AXS Inc., Madison, Wisconsin, USA.
 Ishiguro, T. (1936). *J. Pharmacol. Soc. Jpn.* **56**, 444–452.
 Lin-Gen, Z., Seligmann, O., Lotter, H. & Wagner, H. (1983). *Phytochemistry*, **22**, 265–267.
 Sheldrick, G. M. (1996). *SADABS*. University of Göttingen, Germany.
 Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
 Silva, R. da, de Souza, G. H. B., da Silva, A. A., de Souza, V. A., Pereira, A. C., de Royo, V. A., e Silva, M. L. A., Donate, P. M., de Matos Araujo, A. L. S., Carvalho, J. C. T. & Bastos, J. K. (2005). *Bioorg. Med. Chem. Lett.* **15**, 1033–1037.
 Souza, G. H. B., da Silva Filho, A. A., de Souza, V. A., Pereira, A. C., de Royo, V. A., e Silva, M. L. A., da Silva, R., Donate, P. M., Carvalho, J. C. T. & Bastos, J. K. (2004). *Il Farmaco*, **59**, 55–61.
 Souza, V. A. de, da Silva, R., Pereira, A. C., de Royo, V. A., Saraiva, J., Montanheiro, M., de Souza, G. H. B., da Silva Filho, A. A., Grando, M. D. & Donate, P. M. (2005). *Bioorg. Med. Chem. Lett.* **15**, 303–307.
 Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
 Usubillaga, A., Khouri, N., Cedillo-Vaz, S. & Yibirin, E. (2005). *Acta Hortic.* **677**, 85–89.
 Westrip, S. P. (2007). *publCIF*. In preparation.